Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kids with severe eczema: drug trial shows promise

NCT ID NCT05388760

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 33 times

Summary

This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe and effective. Children received injections over many weeks and used moisturizer daily. The drug aims to control the disease, not cure it, and ongoing treatment may be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • LEO Pharma Investigational Site

    Brno, 625 00, Czechia

  • LEO Pharma Investigational Site

    Prague, 150 06, Czechia

  • LEO Pharma Investigational Site

    Reims, Ardennes, 51100, France

  • LEO Pharma Investigational Site

    Rotterdam, 3011 TG, Netherlands

  • LEO Pharma Investigational Site

    Utrecht, 3584 CX, Netherlands

  • LEO Pharma Investigational Site

    Cadiz, Andalusia, 11009, Spain

  • LEO Pharma Investigational Site

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • LEO Pharma Investigational Site

    Alicante, 03010, Spain

  • LEO Pharma Investigational Site

    Manchester, Greater Manchester, M13 9WL, United Kingdom

  • LEO Pharma Investigational Site

    London, SE1 9RT, United Kingdom

  • LEO Pharma Investigational Site

    Sheffield, S10 2TH, United Kingdom

Conditions

Explore the condition pages connected to this study.